Scheffler-Mendoza S, Partida-Gaytán A, Yamazaki-Nakashimada M

Language: Spanish
References: 16
Page: 323-331
PDF size: 398.15 Kb.

ABSTRACT

Human immunoglobulin replacement therapy has become a cornerstone in the treatment of patients with primary immunodeficiencies (PID). Currently indicated as first-line therapy for predominantly antibody deficiencies, severe combined immunodeficiencies, and some well-defined syndromes with immunodeficiencies, it is also indicated as adjunct therapy in many other PID. Although considered a high-cost medication, elegant studies had showed that patients correctly treated with human immunoglobulin replacement therapy result in lower costs derived from their healthattention. Major benefits of immunoglobulin replacement therapy include but are not restricted to: protection against infectious processes, organ damage progression-arrest, immune modulation and quality-of-life improvement. Two modalities of treatment are currently used, intravenous and subcutaneous, each has clear advantages and disadvantages when compared to the other, which are presented in this article. The correct use of human immunoglobulin for the treatment of patients with PID translates in better medical-practices improving survival and quality of life of affected patients.

REFERENCES

1. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182-94. Epub 2010/01/01.

2. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics: targets & therapy. 2012;6:277-87. Epub 2012/09/08.

3. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am. 2008;28(4):737-64, viii. Epub 2008/10/23.

4. Wood P. Human normal immunoglobulin in the treatment of primary immunodeficiency diseases. Therapeutics and clinical risk management. 2012;8:157-67. Epub 2012/05/02.

5. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exper Immunol. 2011;164 Suppl 2:2-5. Epub 2011/04/16.

6. Lin JH, Wang KY, Kraft S, Roberts RL. Resolution of warts in association with subcutaneous immunoglobulin in immune deficiency. Pediatr Dermatol. 2009;26(2):155-8. Epub 2009/05/08.

7. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525-53. Epub 2006/04/04.

8. Condino-Neto A, Costa-Carvalho BT, Grumach AS, King A, Bezrodnik L, Oleastro M, et al. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. Allergol Immunopathol. 2013. Epub 2013/01/22. Acta Pediátrica de México Volumen 34, Núm. 6, noviembre-diciembre, 2013 331 Inmunoglobulina humana en inmunodeficiencias primarias

9. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clinical Immunol. 2010;125(6):1354-60 e4. Epub 2010/05/18.

10. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology. 2005 May;94(5 Suppl 1):S1- 63. PubMed PMID: 15945566.

11. Carlos J. Montoya G. RUS. Lecciones sobre el uso de gammaglobulina humana endovenosa 2004 June 5th, 2013. Available from: http://www.lagid.lsuhsc.edu/Tratamientos/971-010.htm.

12. Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exper Immunol. 2012;169(2):172-81. PubMed PMID: 22774992. Pubmed Central PMCID: 3406377.

13. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32(6):1180-92. PubMed PMID: 22730009.

14. Condino-Neto A, Costa-Carvalho BT, Grumach AS, King A, Bezrodnik L, Oleastro M, et al. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. Allergol Immunopathol. 2013 Jan 17. PubMed PMID: 23333411.

15. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21-30. PubMed PMID: 20675197.

16. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1):210-2. PubMed PMID: 18602574.